posted stronger-than-expected third quarter earnings Tuesday, while boosting its full-year profit forecast, thanks in part to solid gains for its new cancer treatments.
Pharmaceuticals sales were up 5.1% to $13.9 billion while Medtech sales jumped 10% to $7.46 billion. Consumer health sales were spun-off to Kenvue, the group's stand-alone entity, earlier this year.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Australia Australia Latest News, Australia Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
Source: MarketWatch - 🏆 3. / 97 Read more »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
Source: MarketWatch - 🏆 3. / 97 Read more »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Source: NBCLA - 🏆 319. / 59 Read more »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Source: NBCNewYork - 🏆 270. / 63 Read more »
Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
Source: MarketWatch - 🏆 3. / 97 Read more »